Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Using an AI drug discovery program, Mydecine (MYCO) successfully added a novel psilocin analogue with improved delivery and stability to its pipeline.
The AI technology synthesizes billions of drug candidates and filters them based on psychedelic-related targets such as how they bind to receptors.
Mydecine also filed a patent for nanoemulsion technology that can:
- help the company develop compounds inspired by traditional plant medicines such as reishi and cordyceps mushrooms
- improve control in delivery, which is critical in microdosing and customizing dosages
- advance development of over-the-counter consumer products